ZURICH (Reuters) - Novartis (S:NOVN) Chief Executive Vas Narasimhan said spinal muscular atrophy patients who got the Swiss drugmaker's Zolgensma maintained improvements, a response to Biogen's (O:BIIB) plan to test its drug Spinraza after Zolgensma treatment.
"To date, we have not seen any decline in Zolgensma patients who have received this therapy," Narasimhan told analysts on a call on Tuesday after Biogen's announcement. "In fact, in our clinical trial data, as well as in the real world, we see patients maintaining the milestones they gained with Zolgensma."